U.S. Markets close in 5 hrs 39 mins

MERCK Kommanditgesellschaft auf Aktien (MRK.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
191.05+1.05 (+0.55%)
As of 04:05PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close190.00
Bid190.85 x 6700
Ask191.05 x 11200
Day's Range186.80 - 191.50
52 Week Range126.60 - 231.50
Avg. Volume337,428
Market Cap83.064B
Beta (5Y Monthly)0.45
PE Ratio (TTM)30.92
EPS (TTM)6.18
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & Yield1.40 (0.63%)
Ex-Dividend DateApr 26, 2021
1y Target Est223.67
  • Reuters

    German chip chemical supplier Merck to invest 500 million euros in Taiwan

    German supplier of chemicals and materials used in making semiconductors, Merck KGaA, announced on Tuesday it is to invest 500 million euros in Taiwan over the next five to seven years, primarily in semiconductor technologies. Merck said it would be its largest investment in Taiwan since it established operations there in 1989. "We strengthen our local production and new capabilities to support fast-growing semiconductor demand in Taiwan but also to cater to an increasing demand in the rest of the world," Beckmann said, adding that the investment would expand Merck's footprint in the island's southern city of Kaohsiung. Merck's announcement follows that of Taiwan Semiconductor Manufacturing Co Ltd (TSMC) last month, when the world's largest contract chip maker said it will set up a new chip factory in Kaohsiung to boost production amid a global chip shortage.

  • MarketWatch

    Merck KGaA invests nearly $700 million into venture capital arm M Ventures

    Merck KGaA said Wednesday it will invest an additional 600 million euros (about $680 million) into its corporate venture capital arm M Ventures over the next five years. That's the third increase in financial commitment announced by the Germany-based science and technology company since M Ventures' inception in 2009. "Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems," said Merck KGaA Chief Executive Belén Garijo.